Strong clinical data doesn’t just move share prices – it can unlock lucrative global licensing deals for ASX-listed ...

Pfizer Inc. ($PFE) is returning to the U.S. debt markets with a fresh corporate bond offering aimed at raising at least $5 ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

Pfizer eventually increased its offer. The company is now set to acquire Metsera in a deal worth up to $10 billion, including ...

The deals keeps coming. Merck this morning said it will acquire Cidara Therapeutics, the maker of an experimental flu therapy ...

Pfizer has officially closed on its $10 billion purchase of obesity drug maker Metsera. So what does everyone think of the ...

Pfizer officially buys Metsera; Zealand halts early obesity drug; ESPN, Zepbound and the twilight of the middleman.

Pfizer beats Q3 estimates, raises FY guidance, acquires Metsera for obesity drugs, and offers a 7% yield. Read here for an ...

US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to ...

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...

Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major ...

Pfizer noted it has completed its acquisition of all outstanding shares of the company’s common stock for $65.60 per share in ...